ES-FSG-FO-00218-WD

part of ISSN: 1479-6694 Future ONCOLOGY Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Nicolas Girard Reprinted From: Future Oncol. (2018) (Epub ahead of print)

RkJQdWJsaXNoZXIy MzQyNTUz